Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.
Latest from Adam Zamecnik
After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.
After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.
As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.